Sign In
Buy CDXC
$7.87
+0 (+0%)
At Close: Jun 17, 2025
This Bioscience Company Is Trying To Defy The Aging Process
01:13pm, Friday, 12'th Feb 2021
ChromaDex was one of the sponsors for the Benzinga Global Small Cap Conference that took place on December 8-9, 2020. The information contained in this article in no way represents investment advice o
New Study Results Finds Nutritional Protocol Including Nicotinamide Riboside Reduces Liver Fat and Improves Liver Function
06:35am, Thursday, 04'th Feb 2021
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ: CDXC) today announced results from the study “Combined Metabolic Cofactor Supplementation Reduces Liver Fat in Nonalc
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) announced today the initiation of a human clinical trial of Niagen® (nicotinamide riboside, or NR) investigating
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) announced today the exclusive launch of its TRU NIAGEN® EX Stick Packs with Watsons Hong Kong, available online a
Chromadex: The Little Company That Could
07:38am, Sunday, 08'th Nov 2020
Tru Niagen, CDXC's patented product, shows strong promise in billion dollar markets. Market underestimates monopoly length by ~3x.
ChromaDex's (CDXC) CEO Rob Fried on Q3 2020 Results - Earnings Call Transcript
10:42pm, Wednesday, 04'th Nov 2020
ChromaDex's (CDXC) CEO Rob Fried on Q3 2020 Results - Earnings Call Transcript
Preview: ChromaDex's Earnings
10:09am, Tuesday, 03'rd Nov 2020
On Wednesday, November 04, ChromaDex (NASDAQ: CDXC) will release its latest earnings report. Check out Benzinga's preview to understand the implications.
ChromaDex to Report Third Quarter 2020 Financial Results on Wednesday, November 4, 2020
06:35am, Wednesday, 28'th Oct 2020
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed., November 4, 2020 at 4:30 p.m. ET to discuss its financial r
New Study from NIH Finds Nicotinamide Riboside Helps Improve Telomere Dysfunction in Human Cells, Mice
12:00am, Monday, 19'th Oct 2020
ChromaDex Corp. (NASDAQ:CDXC) today highlighted a new study published in The European Molecular Biology Organization Journal looking at the effect of
Celltrient™ Cellular Energy Products Featuring Tru Niagen® Launch in US
12:00am, Wednesday, 14'th Oct 2020
ChromaDex Corp. (NASDAQ:CDXC) today announced its flagship ingredient, Tru Niagen®, is now available in Nestlé Health Science’s new Celltrient™ Cellul
ChromaDex: Blazing Ahead Of Ponce De Leon (NASDAQ:CDXC)
01:08pm, Sunday, 11'th Oct 2020
Recent study shows nutritional protocol including nicotinamide riboside plus standard of care reduces recovery time by nearly 30%; Phase 3 clinical trial is underway.
New Preclinical Study Finds Nicotinamide Riboside May Improve Immune Cell Function
12:00am, Thursday, 08'th Oct 2020
ChromaDex Corp. (NASDAQ:CDXC) today highlighted a new study from Nature Immunology that found nicotinamide riboside (NR) helped energize tumor infiltr
ChromaDex Corp. (NASDAQ:CDXC) today announced that results from the study “Combined metabolic cofactor supplementation accelerates recovery in mild-to
ChromaDex : to Present at the LD 500 Virtual Investor Conference | MarketScreener
10:33am, Wednesday, 26'th Aug 2020ChromaDex to Present at the LD 500 Virtual Investor Conference
12:00am, Wednesday, 26'th Aug 2020
ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting
